 |
11 Diseases |  |
0 Trials |
|
0 Trials |  |
28 News |  |
- ||| Rescula (unoprostone isopropyl) / Santen, Mallinckrodt, Mikelan (carteolol) / Senju
Journal, Adverse events: Topical ophthalmic beta-blockers are associated with ocular pseudopemphigoid: A pharmacovigilance study of antiglaucoma medications utilising the FDA adverse event reporting system. (Pubmed Central) - May 20, 2022
Our findings support an association between OPP and antiglaucoma medications; under the most stringent control for topical irritant/preservative effect by of comparison to topical eye drops, unoprostone, carteolol, betaxolol and timolol all had a significant ROR for OPP.
- || Vyzulta (latanoprostene bunod) / Bausch Health, Nicox
Retrospective data, Review, Journal: Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. (Pubmed Central) - Apr 26, 2022
LBN was significantly more effective than the PGA unoprostone and most of the beta-blockers. Compared with the most widely used PGAs, LBN numerically outperformed latanoprost and travoprost and was similar to bimatoprost 0.01%.
- | Rescula (unoprostone isopropyl) / Santen, Mallinckrodt, Lumigan (bimatoprost) / Senju, AbbVie
Journal: Effect of prostaglandin analogs: Latanoprost, bimatoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human trabecular meshwork endothelial cells. (Pubmed Central) - Dec 18, 2020
Zymography results show that all three PGAs except unoprostone increased intermediate MMP-1 activity while bimatoprost and latanoprost increased MMP-9 activity. Together, these data suggest that the balance between MMPs and TIMPs correlate to the relative intraocular pressure lowering effectiveness observed in clinical studies of these PGAs.
- || Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Retrospective data, Review, Journal: The influence of topical non-steroidal anti-inflammatory drugs on the intraocular pressure lowering effect of topical prostaglandin analogues-A systemic review and meta-analysis. (Pubmed Central) - Nov 6, 2020
Together, these data suggest that the balance between MMPs and TIMPs correlate to the relative intraocular pressure lowering effectiveness observed in clinical studies of these PGAs. Results of our meta-analysis suggested that topical NSAIDs may enhance the IOP lowering effect of topical PGs in glaucoma patients.
- || Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Clinical, Review, Journal: Discovery, characterization, and clinical utility of prostaglandin agonists for the treatment of glaucoma. (Pubmed Central) - Jul 5, 2020
This afforded the first marketed FP-class PG agonist analog (FP-PGA) ocular hypotensive agent, latanoprost. Since the introduction of latanoprost into clinical medicine to lower and control IOP, a number of additional FP-PGAs have been discovered, characterized and marketed, including travoprost, tafluprost, unoprostone isopropyl ester, and bimatoprost (an amide).
- | Rescula (unoprostone isopropyl) / Santen, Mallinckrodt
Trial termination, Trial primary completion date: Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa (clinicaltrials.gov) - Jan 30, 2016
P3, N=202, Terminated, Sponsor: R-Tech Ueno, Ltd.
Since the introduction of latanoprost into clinical medicine to lower and control IOP, a number of additional FP-PGAs have been discovered, characterized and marketed, including travoprost, tafluprost, unoprostone isopropyl ester, and bimatoprost (an amide). Active, not recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Apr 2015
- ||||| Rescula (unoprostone isopropyl) / Santen, Mallinckrodt
Enrollment closed: Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa (clinicaltrials.gov) - Oct 16, 2013
P3, N=180, Active, not recruiting, Sponsor: R-Tech Ueno, Ltd.
Active, not recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Apr 2015 Recruiting --> Active, not recruiting
- | Rescula (unoprostone isopropyl) / Santen, Mallinckrodt
Trial completion: A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration (clinicaltrials.gov) - Mar 20, 2013
P2, N=33, Completed, Sponsor: Sucampo Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||||||||| Rescula (unoprostone isopropyl) / Santen, Mallinckrodt
New P3 trial: Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa (clinicaltrials.gov) - Feb 6, 2013
P3, N=180, Active, not recruiting, Sponsor: R-Tech Ueno, Ltd.